RECURRENT URETHRAL UROTHELIAL CARCINOMA
Clinical trials for RECURRENT URETHRAL UROTHELIAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT URETHRAL UROTHELIAL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT URETHRAL UROTHELIAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for bladder cancer patients who Can't take standard chemo
Disease control OngoingThis study tests whether adding the chemotherapy drug eribulin to the immunotherapy atezolizumab works better than atezolizumab alone for people with advanced bladder cancer that has spread or come back. The trial includes 72 adults whose cancer cannot be treated with the standar…
Matched conditions: RECURRENT URETHRAL UROTHELIAL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 02:59 UTC
-
New drug combo shows promise for Tough-to-Treat bladder cancer
Disease control OngoingThis early-phase trial tests a combination of two drugs—erdafitinib and enfortumab vedotin—for people with advanced bladder cancer that has spread and has specific changes in the FGFR2/3 genes. The study includes about 24 adults whose cancer worsened after standard chemotherapy. …
Matched conditions: RECURRENT URETHRAL UROTHELIAL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 26, 2026 19:38 UTC
-
Can a gene test tell who will respond to immunotherapy?
Knowledge-focused OngoingThis study looks at whether certain genetic changes in tumors can help predict if the immunotherapy drug nivolumab will work for people with advanced bladder cancer that has spread. Researchers are testing tumor samples for specific gene mutations and a protein called CXCL13. The…
Matched conditions: RECURRENT URETHRAL UROTHELIAL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated May 17, 2026 03:00 UTC